• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Category: Publications

Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study.

Posted: 2019-06-18

Yesterday, our latest publication, Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study was published online in the European Journal of Contraception and Reproductive Health Care.

The study was aimed at estimating the real-use contraceptive effectiveness of the combined oral contraceptive (COC) containing dienogest and oestradiol valerate (DNG/oEV) compared to other combined oral contraceptives (oCOC) and particularly, levonorgestrel-containing OCs (LNG).

The results confirmed that DNG/oEV showed improved contraceptive effectiveness compared with oCOC and particularly LNG-COC when adjusted for age, parity, user status, and smoking

Filed Under: News, Publications

Real world data on Nexplanon® procedure-related events: final results from the Nexplanon observational risk assessment study (NORA)

Posted: 2019-06-18

Our latest publication, Real-world data on Nexplanon® procedure-related events: final results from the Nexplanon observational risk assessment study (NORA) has just been published in Contraception.

The study was aimed to characterize the frequency of insertion-, localization- and removal-related events and their clinically significant consequences among Nexplanon® (etonogestrel radiopaque contraceptive implant) users in the United States during standard clinical practice.

The finds confirmed that events associated with the insertion, localization, and removal of the Nexplanon contraceptive implant were rare and their clinical consequences were generally not suggestive of serious injury.

The study demonstrates that complications associated with insertion and removal of Nexplanon are rare when performed by trained clinicians.

Filed Under: News, Publications

Final results of from the EURAS-IUD extension study

Posted: 2018-01-11

Our latest publication, Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study, has just been published in the European Journal of Contraception and Reproductive Health Care.  This landmark observational study followed women for 5 years and identified intra-uterine device (IUD) perforations dectected from 12 to 60 months following IUD insertion.

The incidence of uterine perforations in this study was low, although higher than the commonly reported rate.  Clinical sequalae of perforations were generally mild and associated with a very low risk of injury.  You can download the full text of article using this link: Full Article

 

Filed Under: Publications

sidebar

Library & News

  • News/Conferences
  • Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.